It belongs to a class of medications known as Janus Kinase (JAK) inhibitors. This medicine is used to treat rheumatoid arthritis. Please call us or submit an enquiry form before making an application. There are six patents protecting this drug. [5][9], Upadacitinib seems to be a weak inducer of CYP3A4, as it lowers concentrations of other substrates of this enzyme (such as the midazolam AUC by 26%). Register your property as a film location today and gain access to Location London’s expansive network of production managers and location scouts. In this study, the safety profile of RINVOQ was consistent with that observed in previously reported studies in patients with rheumatoid arthritis, with no new safety risks detected. Rinvoq will be sold for $59,000 a year in the U.S. Humira, also manufactured by AbbVie and indicated in the treatment of RA, costs an estimated $5,174 for a four-week supply, coming in at an annual cost of over $60,000. Adverse events included headache, nausea, and infection but no infections were serious. [7], Trial 3 enrolled participants in whom DMARDS did not work well. Coverage means placed on formulary without a step edit through other biologics. [22][7], The U.S. Food and Drug Administration (FDA) approved upadacitinib based on evidence from five clinical trials (Trial 1/NCT02706873, Trial 2/NCT02706951, Trial 3/NCT02675426, Trial 4/NCT02629159, Trial 5/NCT02706847) of 3,141 participants with active rheumatoid arthritis (RA). At week 26, more patients on upadacitinib vs placebo or adalimumab achieved low disease activity or remission (p≤0.001). [5][9], The use of upadacitinib in combination with other Janus kinase inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and ciclosporin is not recommended. You can connect with RINVOQ on Facebook or by phone at 1-800-2-RINVOQ. [7] At week 12, participants who received placebo were re-assigned to upadacitinib daily. No interaction was found in rheumatoid arthritis patients taking methotrexate. I want to list my house as a filming location – How much should I charge for my property to be used in a film or movie?. In the second phase IIb study, 300 rheumatoid arthritis patients were recruited who have had an inadequate response to methotrexate. [4][3], The drug is contraindicated in people with active tuberculosis and other severe infections, severe liver impairment (Child–Pugh score C), and during pregnancy. Walking distance to local pub with beer garden. Rinvoq (upadacitinib) may not be approved for the following: Market Applicability Market GA KY MD NJ NY WA Applicable X X X X X NA PAGE 2 of 3 11/01/2020 New Program Date 09/05/2019 This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. [5][9], The drug is excreted mainly as the original substance, of which 38% are found in the feces and 24% in the urine. [7], Upadacitinib was approved for medical use in the European Union in December 2019. Because each location in every film, commercial, TV series, and photo shoot is very deliberately chosen, yours might be the one they're looking for. Call +44 (0) 20 7629 1111 Search locations Register your location Wishlist help. None are pharmacologically active. [7], Trial 5 enrolled participants in whom DMARDS did not work well or could not be tolerated. SHOOTFACTORY is a London Location Agency representing high end residential property, studios, commercial and industrial spaces and quirky locations, for the purposes of photographic, filming and event productions. This benefit covers RINVOQ ™ (upadacitinib) alone or for RINVOQ plus one of the following medications: methotrexate, leflunomide (Arava ®), or hydroxychloroquine (Plaquenil ®).Eligibility: Available to patients with commercial prescription insurance coverage for RINVOQ who meet eligibility criteria. It has no effect on substrates of CYP1A2, CYP2B6, CYP2C9, CYP2C19 or CYP2D6. 27% of patients taking the 6 mg twice daily dose achieved clinical remission compared to 11% of patients taking placebo. [7] hsCRP is a substance produced by the body to protect itself from illness. Commercial & Industrial . [7], Trial 1 enrolled participants who had never been treated with MTX. [19], SELECT-CHOICE was a phase III trial comparing upadacitinib and abatacept in 612 people whose rheumatoid arthritis did not respond to biologic DMARDs. 1,2 Through week 24, serious infections occurred in 0.5/2.8 percent of patients in the 15/30 mg RINVOQ groups, respectively, compared to 0.5 percent in the placebo group. However, the first generation of these drugs, tofacitinib and ruxolitinib, lacked subtype selectivity, affecting JAK1/JAK3 and JAK1/JAK2 respectively. This has led to dose-limiting side effects in this otherwise promising class of drugs. Three malignancies, five MACE, and four deaths were reported, none on upadacitinib. I believe he is the same actor in the Maytag [7] At week 14, participants who were assigned to MTX received upadacitinib by mouth daily. Its effectiveness is currently being studied for other types of arthritis. One case of community-acquired pneumonia occurred at 12 mg. [needs update] Available to patients between the ages of 18-63 with commercial prescription insurance coverage who meet eligibility criteria. (62%, 68%, 80%, 64%, and 76% for the 3, 6, 12, 18, and 24 mg doses, respectively) than with placebo (46%). The primary endpoint was a 20% improvement in symptoms according to the American College of Rheumatology improvement criteria (ACR20). Nearly every movie, commercial, and television series filming or planning to film in the greater Los Angeles area makes contact with Real to Reel at some point in the production process for one or more of their location requirements. [13] Inhibition of CYP3A by ketoconazole increased total AUC, indicating the importance of this metabolic route. [7], Trial 2 enrolled participants in whom MTX did not work well. Rinvoq is used to treat adults with moderate to severe rheumatoid arthritis in patients that could not tolerate methotrexate or if treatment with methotrexate did not work well. Partnering with larger property groups, to individual homeowners, our dedicated support team will be on hand to ensure that your location is matched with the hottest filming projects in London. Adverse events did not appear to be dose-related. An investigation into absorption and metabolism found that dosing after a high-fat meal had no effect on upadacitinib total drug exposure over time (area under the curve or AUC). The Location House Kent and Private Bar Kent are set in two separate buildings at the same location. Commercial & Industrial Photo Shoot, TV and Film Locations to Hire in London. The most important pathway consists of oxidation to a carboxylic acid and subsequent glucuronidation, yielding a metabolite called M4. Rinvoq works by suppressing the immune system. As such, our content is blocked by ad blockers. At 16 weeks 22% of patients taking the 24 mg twice daily dose achieved endoscopic remission with upadacitinib compared to 0% of patients taking placebo. [7] ACR20 is a 20% improvement in signs and symptoms of RA. Eligible patients must have (1) commercial insurance, (2) a valid Rx for RINVOQ, and (3) experienced a delay or denial in insurance determination. [15] Patients were randomized to receive 3, 6, 12, or 18 mg twice daily or placebo. Both are available for commercial filming/photographic shoots. By order of state and local authorities, on-location filming was completely shut down in the City and County of Los Angeles from March 20 through June 11, due to the COVID-19 pandemic. Medicare coverage and pricing details for Rinvoq. [18] Two Phase III trials are planned studying participants with psoriatic arthritis and one in participants with ulcerative colitis. * In these difficult times, it's important to restrict non-essential travel so, stay safe. In the past 30 days, RINVOQ has had 3,613 airings and earned an airing rank of #279 with a spend ranking of #49 as compared to all other advertisers. A fatty meal has no clinically relevant effect on its resorption. Six venous thromboembolic events were reported [placebo, one; upadacitinib, two; adalimumab, three]. In this 16-week study, 220 patients were recruited with moderately to severely active Crohn's disease. [7] Participants were randomly assigned to receive one of two doses of upadacitinib or placebo daily by mouth in addition to DMARDS for 12 weeks. The most common adverse event was headache but its incidence was similar to that when taking placebo (15.6% for upadacitinib vs. 16.7% for placebo). For example, rifampicin reduced the AUC by 60% in a study. Rinvoq (upadacitinib) is a Disease Modifying Anti-Rheumatic Drug (DMARD) that’s currently used to treat rheumatoid arthritis with and without methotrexate. Other metabolites are only present in small fractions. [7] Participants were randomly assigned to receive one of two doses of upadacitinib or MTX daily for 24 weeks. Watch, interact and learn more about the songs, characters, and celebrities that appear in your favorite RINVOQ TV Commercials. [7] Neither the subject nor the healthcare providers knew which medication was being given. Secondary endpoints included significant clinical response (≥30% reduction in symptoms) at week 16 and endoscopic response (≥25% decrease in symptoms) at week 12 or 16. [12], After oral intake, upadacitinib reaches highest concentrations in the blood plasma after two to four hours. COVID-19 UPDATE - 26.01.2021 Due to the National lockdown, we are unable to facilitate shoots and recces at some of our locations. Rinvoq plus MTX achieved ACR20 vs 36% for placebo plus MTX at Week 12 Study RA-V showed that 65% of patients who had an inadequate response or intolerance to biologic DMARDs treated with Rinvoq plus cDMARDs achieved ACR20 vs 28% treated with placebo plus cDMARDs at Week 12 A higher proportion of patients treated with Rinvoq A phase I study revealed that upadacitinib followed a bi-exponential disposition with a terminal half-life of 6–16 hours. When do Rinvoq patents expire, and when can generic versions of Rinvoq launch? [20][21], Upadacitinib was approved for medical use in the United States in August 2019. [6] There was no significant accumulation over the dose range of 3–36 mg per day. [3], Substances that strongly inhibit the liver enzyme CYP3A4, such as ketoconazole, itraconazole or clarithromycin, increase upadacitinib concentrations in the body. [14] Patients were randomized to receive 3, 6, 12, or 18 mg twice daily or placebo. [7] Participants were randomly assigned to receive one of two doses of upadacitinib or placebo treatment daily added to DMARDs for 12 weeks. There is no significant first pass effect. The mean terminal half-life is 9 to 14 hours.[5][9]. [7] Neither the subject nor the healthcare providers knew which medication was being given. Call +44 (0) 20 7629 1111. A single case of non-melanoma skin cancer was reported in the 24 mg twice daily group. [7], Trial 4 enrolled participants in whom MTX did not work well. The proportions of patients with serious AEs and AEs leading to discontinuation were highest for adalimumab; the proportion with herpes zoster and CPK elevations was highest for upadacitinib. In the first study, 276 rheumatoid arthritis patients were recruited who had previously experienced inadequate response to anti–tumor necrosis factor (TNF) therapy and were currently on a stable dose of methotrexate. It can take a full week to get enough footage for a 30-second advertisement. [4], Upadacitinib is indicated for the treatment of moderate to severe active rheumatoid arthritis in adults who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (DMARDs). National commercial coverage as of April 2020. [7] At week 26, all participants receiving placebo were switched to upadacitinib once daily by mouth. Each request will be reviewed on a case by case basis. Further information is available on our safety guidance page.. We thank you for your continued patience. Radiographic progression was less and observed in fewer patients receiving upadacitinib versus placebo (p≤0.001). [5][9], The Janus kinases (JAKs) are a family of cytoplasmic tyrosine kinases whose function is to transduce cytokine-mediated signals via the JAK-STAT pathway. [7] It was approved for medical use in the United States and in the European Union in 2019,[7][8][4] and was developed by the biotech company AbbVie. [16][17] Patients were randomized to therapy with upadacitinib at 3, 6, 12, 24 mg twice daily or 24 mg once daily for 16 weeks or placebo, followed by blinded extension therapy for 36 weeks. [5][9], Common side effects are upper respiratory tract infections such as common cold and sinus infections (13.5% of patients in studies), nausea (3.5%), cough (2.2%), fever, and increased liver enzymes. Download our filming locations brochure We have diverse portfolio of filming spaces, including a wartime bunker, a Second World War battleship, an airfield and two stunning modern museums. Please consider disabling your ad blocker on this site to ensure the best user experience. [7] At week 12, participants who received placebo were re-assigned to upadacitinib daily. Yes, there is excitement in a car commercial, but in the production stages, there’s more drudgery and persistence. Data on File, AbbVie Inc. Payer-reported lives. Upadacitinib was superior to adalimumab for ACR50, DAS28CRP≤3.2, ΔPain and ΔHAQDI. There are four JAK subtypes, each of which has overlapping receptor responsibilities. A team of 4 specialist location advisors, dedicated to listening to your filming location needs, and actively working with you to find the perfect film location solution for your project. It is mainly metabolized by CYP3A4, and possibly to a minor extent by CYP2D6. [4], CCC1CN(CC1C2=CN=C3N2C4=C(NC=C4)N=C3)C(=O)NCC(F)(F)F, InChI=1S/C17H19F3N6O/c1-2-10-7-25(16(27)24-9-17(18,19)20)8-11(10)13-5-22-14-6-23-15-12(26(13)14)3-4-21-15/h3-6,10-11,21H,2,7-9H2,1H3,(H,24,27)/t10-,11+/m1/s1, Learn how and when to remove this template message, "Upadacitinib (Rinvoq) Use During Pregnancy", "Rinvoq 15 mg prolonged-release tablets - Summary of Product Characteristics (SmPC)", "Rinvoq- upadacitinib tablet, extended release", "Rinvoq: EPAR – Public assessment report", "AbbVie Receives FDA Approval of RINVOQ (upadacitinib), an Oral JAK Inhibitor for the Treatment of Moderate to Severe Rheumatoid Arthritis", "Characterization of ABT-494, a Second Generation Jak1 Selective Inhibitor", "Assessment of effect of CYP3A inhibition, CYP induction, OATP1B inhibition, and high-fat meal on pharmacokinetics of the JAK1 inhibitor upadacitinib", "A Phase IIb Study of ABT-494, a Selective JAK-1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Therapy", "Efficacy and Safety of ABT-494, a Selective JAK-1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate", "A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of ABT-494 for the Induction of Symptomatic and Endoscopic Remission in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Immunomodulators or Anti-TNF Therapy - Full Text View - ClinicalTrials.gov", "AbbVie Announces Positive Phase 2 Study Results for Upadacitinib (ABT-494), an Investigational JAK1-Selective Inhibitor, in Crohn's Disease", "Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis", "A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs", Methoxy polyethylene glycol-epoetin beta (CERA/Mircera), Granulocyte macrophage colony-stimulating factor, Interferon alpha (interferon alfa, IFN-α), FMS-like tyrosine kinase 3 ligand (FLT3L), Leukemia/leukocyte inhibitory factor (LIF), Signaling peptide/protein receptor modulators, https://en.wikipedia.org/w/index.php?title=Upadacitinib&oldid=996496491, Short description is different from Wikidata, All Wikipedia articles written in American English, Multiple chemicals in an infobox that need indexing, Articles containing unverified chemical infoboxes, Articles needing additional references from April 2020, All articles needing additional references, Wikipedia articles in need of updating from May 2018, All Wikipedia articles in need of updating, Creative Commons Attribution-ShareAlike License, Mainly unchanged in feces (38%) and urine (24%), This page was last edited on 26 December 2020, at 23:26.